GSE207410 GSE207411 ARID1A knockdown 1 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE207410_GSE207411_ARID1A knockdown_1_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE207410_GSE207411_ARID1A knockdown_1_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE207410_GSE207411_ARID1A knockdown_1_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE207410_GSE207411_ARID1A knockdown_1_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

growth arrest specific 5

Gene

MSL complex subunit 3B

Gene

small nucleolar RNA host gene 3

Gene

DExD-box helicase 52

Gene

tripartite motif containing 16 like (pseudogene)

Gene

GOLGA2 pseudogene 7

Gene

lung cancer associated transcript 1

Gene

H3 clustered histone 6

Gene

NmrA like redox sensor 2, pseudogene

Gene

NR2F1 regulatory antisense RNA 1

  • Gene

    growth arrest specific 5


  • Gene

    MSL complex subunit 3B


  • Gene

    small nucleolar RNA host gene 3


  • Gene

    DExD-box helicase 52


  • Gene

    tripartite motif containing 16 like (pseudogene)


  • Gene

    GOLGA2 pseudogene 7


  • Gene

    lung cancer associated transcript 1


  • Gene

    H3 clustered histone 6


  • Gene

    NmrA like redox sensor 2, pseudogene


  • Gene

    NR2F1 regulatory antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.